Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rainer Strotmann

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Plos One|March 26, 2014
Adaptive gene regulation in the Striatum of RGS9-deficient miceKathy Busse, Rainer Strotmann, Karl Strecker, et al.
European Journal of Cell Biology|April 5, 2008
Inflammatory cytokines increase extracellular procathepsin D in permanent and primary endothelial cell culturesSabine Erdmann, Albert Ricken, Katja Hummitzsch, et al.
Expert Review of Endocrinology & Metabolism|February 14, 2019
Molecular basis and clinical features of nephrogenic diabetes insipidusAngela Schulz, Holger Römpler, Doreen Mitschke, et al.
Clinical and Translational Science|September 2, 2024
Explainable machine learning prediction of edema adverse events in patients treated with tepotinibFederico Amato, Rainer Strotmann, Roberto Castello, et al.
Clinical Lung Cancer|July 10, 2024
Tepotinib in a Patient With Advanced Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping Undergoing Concomitant Hemodialysis for Renal Failure: A Case ReportMoritz Kleemiss, Christa E Müller, Marion Schneider, et al.
Clinical and Translational Science|July 18, 2025
Sensitivity of Tepotinib to Inhibitors or Inducers of CYP3A4 and P-Gp: Drug Interaction Studies and Physiologically-Based Pharmacokinetic AnalysisRainer Strotmann, Christian Lüpfert, Axel Krebs-Brown, et al.
Cancer Chemotherapy and Pharmacology|June 30, 2022
Exposure-response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendationsWenyuan Xiong, Sofia Friberg Hietala, Joakim Nyberg, et al.
American Journal of Physiology. Renal Physiology|August 22, 2008
V2 vasopressin receptor deficiency causes changes in expression and function of renal and hypothalamic components involved in electrolyte and water homeostasisNicole Schliebe, Rainer Strotmann, Kathy Busse, et al.
Investigational New Drugs|July 6, 2023
Assessment of the potential of the MET inhibitor tepotinib to affect the pharmacokinetics of CYP3A4 and P-gp substratesÖzkan Yalkinoglu, Andreas Becker, Axel Krebs-Brown, et al.
The Journal of Biological Chemistry|September 24, 2011
Mutually opposite signal modulation by hypothalamic heterodimerization of ghrelin and melanocortin-3 receptorsAnne Rediger, Carolin L Piechowski, Chun-Xia Yi, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Plos One|March 26, 2014
Adaptive gene regulation in the Striatum of RGS9-deficient miceKathy Busse, Rainer Strotmann, Karl Strecker, et al.
European Journal of Cell Biology|April 5, 2008
Inflammatory cytokines increase extracellular procathepsin D in permanent and primary endothelial cell culturesSabine Erdmann, Albert Ricken, Katja Hummitzsch, et al.
Expert Review of Endocrinology & Metabolism|February 14, 2019
Molecular basis and clinical features of nephrogenic diabetes insipidusAngela Schulz, Holger Römpler, Doreen Mitschke, et al.
Clinical and Translational Science|September 2, 2024
Explainable machine learning prediction of edema adverse events in patients treated with tepotinibFederico Amato, Rainer Strotmann, Roberto Castello, et al.
Clinical Lung Cancer|July 10, 2024
Tepotinib in a Patient With Advanced Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping Undergoing Concomitant Hemodialysis for Renal Failure: A Case ReportMoritz Kleemiss, Christa E Müller, Marion Schneider, et al.
Clinical and Translational Science|July 18, 2025
Sensitivity of Tepotinib to Inhibitors or Inducers of CYP3A4 and P-Gp: Drug Interaction Studies and Physiologically-Based Pharmacokinetic AnalysisRainer Strotmann, Christian Lüpfert, Axel Krebs-Brown, et al.
Cancer Chemotherapy and Pharmacology|June 30, 2022
Exposure-response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendationsWenyuan Xiong, Sofia Friberg Hietala, Joakim Nyberg, et al.
American Journal of Physiology. Renal Physiology|August 22, 2008
V2 vasopressin receptor deficiency causes changes in expression and function of renal and hypothalamic components involved in electrolyte and water homeostasisNicole Schliebe, Rainer Strotmann, Kathy Busse, et al.
Investigational New Drugs|July 6, 2023
Assessment of the potential of the MET inhibitor tepotinib to affect the pharmacokinetics of CYP3A4 and P-gp substratesÖzkan Yalkinoglu, Andreas Becker, Axel Krebs-Brown, et al.
The Journal of Biological Chemistry|September 24, 2011
Mutually opposite signal modulation by hypothalamic heterodimerization of ghrelin and melanocortin-3 receptorsAnne Rediger, Carolin L Piechowski, Chun-Xia Yi, et al.
Pageof 3